u/adaeze_cabrera

the discontinuation arms are the interesting part, not the SURPASS endpoints

what is titration — it means going slow on the escalation

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Copay was denial for the copay then another 6% of the total. Read the actual plan document.

resistance training is sarcopenia not optional

Sceptical. If this were true we would see it reflected in the data and we do not.

Did anything else change in the same window?

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

DEXA is the real measurement

update rather than repost, 16 people doing this

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

FFMI tracking requires body composition

off-label use data is different from approved-indication data

Cosigning. The concentration on the vial in marker is load-bearing.

week two nothing happening — yes, that is normal

say which country and which plan type

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.

You have restated the marketing copy. What is the actual substance here.

Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.

Strongly agree. Phase 2 is investigational, not conclusive.

step therapy documentation is the weapon, use it